Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of irinotecan and panitumumab as third-line treatment in metastatic colorectal cancer without KRAS mutations
2008-004923-48Phase 2Terminated
- Sponsor
- Vejle Hospital
- Start
- Aug 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan and panitumumab in metastatic colorectal adenocarcinoma (mCRC), sponsored by Vejle Hospital. Primary endpoint: Response rate. Started Aug 2008; status: terminated.
02
Drugs
irinotecanpanitumumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2008-004923-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004923-48.